MHB048C

MHB048C is a novel **antibody-drug conjugate (ADC)** targeting **prostate-specific membrane antigen (PSMA)**, developed by Minghui Pharmaceutical. It is designed to deliver a DNA topoisomerase I inhibitor (TOP1 inhibitor) as its cytotoxic payload, exploiting high PSMA expression in prostate cancer cells to selectively deliver the chemotherapeutic agent and minimize off-target effects. The antibody component targets PSMA on tumor cells, while the drug-conjugated payload exerts its anticancer effect by inhibiting DNA topoisomerase I, leading to DNA damage and cell death. MHB048C is currently in preclinical and early clinical development for advanced solid tumors, especially metastatic castration-resistant prostate cancer (mCRPC)[1][2][3][5][6][7][9][13][14].